AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04739774
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repeated doses of oral Itraconazole
Trial: NCT06372483
Drug: Rivaroxaban 20 mg Oral Tablet
RxNorm normalized name: rivaroxaban 20 MG Oral Tablet
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fxa DOAC
Trial: NCT06372483
Drug: Apixaban 5 mg Oral Tablet
RxNorm normalized name: apixaban 5 MG Oral Tablet
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fxa DOAC
Trial: NCT06372483
Drug: Edoxaban 60 mg Oral Tablet
RxNorm normalized name: edoxaban 60 MG Oral Tablet
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fxa DOAC
Trial: NCT06547359
Drug: Obicetrapib 10mg
RxNorm normalized name: Obicetrapib
DrugBank: Obicetrapib (DB14890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT04818515
Drug: Atogepant
RxNorm normalized name: Atogepant
DrugBank: Atogepant (DB16098)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral; Tablet
Trial: NCT04818515
Drug: Ubrogepant
RxNorm normalized name: Ubrogepant
DrugBank: Ubrogepant (DB15328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral; Tablet
Trial: NCT06547359
Drug: Ezetimibe 10mg
RxNorm normalized name: EZETIMIBE 10MG TAB
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: tablets
Trial: NCT06059001
Drug: Nab-Paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion - Standard of Care
Trial: NCT06059001
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion - Standard of Care
Trial: NCT05738291
Drug: BI 1839100
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1839100
Trial: NCT05738291
Drug: midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: midazolam
Trial: NCT05738291
Drug: digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: digoxin
Trial: NCT05181475
Drug: Sodium Oligomannate Capsules (GV-971)
RxNorm normalized name: Dantrolene Sodium Capsules
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Oligomannate Capsules, each capsule contains 150 mg of sodium oligomannate. The recommended treatment is oral administration, 450 mg (3 capsules) per dose, bid, in morning and evening.
Trial: NCT04650841
Drug: Placebo Cream with Naloxone
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be informed that the spray is an effective pain and negative emotion reducing agent.
Trial: NCT04650841
Drug: Control Cream with Naloxone
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be informed that the spray is saline.
Trial: NCT06289881
Drug: Sildenafill-Test product
RxNorm normalized name: sildenafil Injectable Product
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test-Product: Sildenafil 100 mg tablets Manufactured by: Actigen Co., Ltd., Thailand
Trial: NCT06289881
Drug: Sildenafill-Reference product
RxNorm normalized name: sildenafil Injectable Product
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference-product: Viagra 100 mg tablets Manufactured by: FAREVA AMBOISE, France
Trial: NCT05810116
Drug: Microcrystalline cellulose
RxNorm normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of 1-2 capsules (1 capsule containing 350mg)
Trial: NCT00002067
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06356597
Drug: Tislelizumab with Fruquintinib, Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole tablets: One administration cycle is every 6 weeks, and metronidazole tablets are given orally on the 1st to 7th day of each cycle. The medication method is two tablets three times one day.~Teralizumab: Every 3 weeks is a dosing cycle, with 200mg of Teralizumab administered intravenously on the first day of each cycle.
Trial: NCT05507164
Drug: Temporomasseteric Nerve Block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The TMNB injection is a local anesthetic injection technique that targets the anterior deep temporal and masseteric branches of the mandibular division of the Trigeminal Nerve. The surface landmark for the twin block injection site is located by palpating for the depression created by the greater wing of the sphenoid bone at the superior border of the zygomatic process and approximately 1 cm posterior to the posterior border of the frontal process of the zygomatic bone. This site is first disinfected with alcohol wipes prior to inserting a 27- or 25-gauge long dental needle (32 mm). Angled 35-45° away from the calvarium (skull) and perpendicular to the zygomatic arch (along the coronal plane), the needle is advanced to its length before injecting 1.8 mL of 2% lidocaine with 1:100,000 epinephrine.
Trial: NCT05783323
Drug: Larotrectinib monotherapy
DrugBank: Larotrectinib (DB14723)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive larotrectinib monotherapy for 6 months at the FDA-approved dose.
Trial: NCT00002238
Drug: Interferon beta-1b
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002238
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05856747
Drug: TBP-PI-HBr
RxNorm normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TBP-PI-HBr tablets.
Trial: NCT06345703
Drug: NS-136 tablet
RxNorm normalized name: NS-2
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational product NS-136
Trial: NCT05907499
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine 6 mg/m2 daily subcutaneously for consecutive 3 days (day 1 to day 3)
Trial: NCT05907499
Drug: Granulocyte Colony-Stimulating Factor
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5ug/kg/d when absolute neutrophil count ≤ 1.5 × 109/L
Trial: NCT05907499
Drug: Thrombopoietin Receptor Agonist
RxNorm normalized name: Thrombopoietin receptor agonist
DrugBank: Thrombopoietin (DB06534)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag initial dose: 25 mg orally once a day, may increase to up to 75 mg/day, when platelet count ≤ 30 × 109/L; Avatrombopag initial dose: 20 mg orally once a day, may increase to up to 60 mg/day, when platelet count ≤ 30 × 109/L.
Trial: NCT05907499
Drug: Recombinant human erythropoietin
RxNorm normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10000 U/day when hemoglobin ≤ 85 g/L
Trial: NCT06270394
Drug: 68Ga-Fibroblast activation protein inhibitor
RxNorm normalized name: Activated protein C
DrugBank: Drotrecogin alfa (DB00055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibroblast activation protein (FAP), a type II transmembrane serine protease with dipeptidyl peptidase and endopeptidase activities. FAP is a specific surface marker for activated fibroblasts in the mesenchyme of tumors, which account for 90% of the stroma of epithelial neoplasms. FAP inhibitors (FAPIs) can specifically target and bind to FAP. These inhibitors that are radiolabeled with gallium 68 (68Ga-FAPIs) can be probes for visualization of the FAP tumor stroma. Previous studies have demonstrated that 68Ga-FAPI-04 is not dependent on blood glucose levels, has an equal or better tumor-to-background ratio, and clearly visualizes primary tumors and their metastatic foci. In addition, previous studies on 68Ga-FAPI-04 have focused on PET/CT and the efficacy of PET/MR with FAPI for postoperative evaluation of GI tumors remains to be clarified.
Trial: NCT04262427
Drug: Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]
RxNorm normalized name: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: potent humanized immunoglobulin (Ig) G4 monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor
Trial: NCT04999293
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients were survivors and treated with DAPT (aspirin \[100 mg once daily\], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist \[clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)\]) at the time of hospital discharge.All patients were followed for 1 year in the outpatient clinic after hospital discharge.
Trial: NCT04792970
Drug: Talc
RxNorm normalized name: Talc
DrugBank: Talc (DB09511)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients randomized to the Talc arm will receive Talc therapy through the pleural catheter.
Trial: NCT06220266
Drug: Diet control & life style modification
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet control \& life style modification
Trial: NCT00000810
Drug: Delavirdine mesylate
RxNorm normalized name: Delavirdine Mesylate
DrugBank: Delavirdine (DB00705)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000810
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000810
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05417386
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of the FOLFIRINOX drug combination, given by intravenous infusion
Trial: NCT05417386
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of the FOLFIRINOX drug combination, given by intravenous infusion
Trial: NCT05417386
Drug: 5-Fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of the FOLFIRINOX drug combination, given by intravenous infusion
Trial: NCT05417386
Drug: NIS793
RxNorm normalized name: Anti-tgf-beta monoclonal antibody nis793
DrugBank: Nisevokitug (DB17561)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by intravenous infusion
Trial: NCT06500689
Drug: Allisartan Isoproxil
RxNorm normalized name: Allisartan isoproxil
DrugBank: Allisartan isoproxil (DB18880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind period (Week 1\~Week 12): Allisartan Isoproxil.~Open-label period (Week 13\~Week 52): Allisartan Isoproxil/Sustained-Release Indapamide.
Trial: NCT05736107
Drug: CBL-514 Injection
RxNorm normalized name: OH-Cbl
DrugBank: Hydroxocobalamin (DB00200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Formulated as an injectable CBL-514 solution at a concentration of 5 mg/mL.
Trial: NCT04887805
Drug: Lenvatinib Mesylate
RxNorm normalized name: Lenvatinib Mesylate
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05287100
Drug: Midodrine Oral Tablet
RxNorm normalized name: midodrine Oral Tablet
DrugBank: Midodrine (DB00211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Midodrine starting at 0.25mg/kg/day in 2-3 divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by \>10% ; Midodrine dosage will be decreased by 25% in case of arterial hypertension (\>95th centile BP for the age). Also Standard medical therapy as per departmental protocol will be continued
Trial: NCT06691841
Drug: Chlorhexidine Gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral wiping and oral care solution rinsing, oral care solution was 0.12% chlorhexidine gluconate, and the frequency of oral care was 3 times a day.
Trial: NCT06695689
Drug: LM303
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with LM303 injection
Trial: NCT05683626
Drug: Humira
RxNorm normalized name: Humira
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subcutaneous injection
Trial: NCT05704049
Drug: Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Investigational medicinal product; Pharmaceutical form: Solution for Subcutaneous administration; Route of administration: Subcutaneous
Trial: NCT05704049
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Investigational medicinal product; Pharmaceutical form: Powder for solution for infusion; Route of administration: Intravenous
Trial: NCT05704049
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Investigational medicinal product/background treatment; ATC code: H02AB02; Pharmaceutical form: Tablet; Route of administration: Oral
Trial: NCT05704049
Drug: Dexamethasone IV
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Investigational medicinal product/background treatment; ATC code: H02AB02; Pharmaceutical form: Powder for solution for infusion; Route of administration: Intravenous
Trial: NCT05704049
Drug: Montelukast
RxNorm normalized name: Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Background Treatment; ATC code: R03DC03; Pharmaceutical form: As per local commercial product; Route of administration: Oral
Trial: NCT05704049
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Background Treatment; ATC code: R06AA02; Pharmaceutical form: As per local commercial product; Route of administration: Oral or IV
Trial: NCT05704049
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Background Treatment/Rescue medication; ATC code: H02AB04; Pharmaceutical form: As per local commercial product; Route of administration: IV
Trial: NCT04857034
Drug: Deucravacitinib
RxNorm normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05067244
Drug: MDMA
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA assisted psychotherapy
Trial: NCT04707183
Drug: Lidocaine IV Infusion
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine will infused through erector spinae plane block catheter in patients with traumatic rib fracture.
Trial: NCT04707183
Drug: 2% Lidocaine via ESPB
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 ml of 2% lidocaine will be infused through ESPB in treatment group
Trial: NCT06025227
Drug: Etrasimod
RxNorm normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT05705128
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine will be given with bupivaciane for postoperative pain control
Trial: NCT04154488
Drug: Mavorixafor
RxNorm normalized name: Mavorixafor
DrugBank: Mavorixafor (DB05501)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavorixafor capsules will be administered per dose and schedule specified in the arm.
Trial: NCT05598307
Drug: magnesium bolus followed by normal saline infusion
RxNorm normalized name: NS-2359
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: a bolus dose of magnesium will be followed by normal saline infusion
Trial: NCT05598307
Drug: magnesium bolus followed by magnesium infusion
RxNorm normalized name: Magnesium
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: a bolus dose of magnesium will be followed by a magnesium infusion
Trial: NCT05598307
Drug: normal saline bolus followed by normal saline infusion
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a bolus of normal saline will be followed by normal saline infusion
Trial: NCT06430411
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered as part of multimodal treatment for oligometastatic prostate cancer
Trial: NCT06430411
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered as part of multimodal treatment for oligometastatic prostate cancer
Trial: NCT06430411
Drug: Darolutamide
RxNorm normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered as part of multimodal treatment for oligometastatic prostate cancer
Trial: NCT06430411
Drug: Apalutamide
RxNorm normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered as part of multimodal treatment for oligometastatic prostate cancer
Trial: NCT06430411
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as part of multimodal treatment for oligometastatic prostate cancer
Trial: NCT06430411
Drug: Lutetium-PSMA
RxNorm normalized name: lutetium
DrugBank: Motexafin lutetium (DB05296)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as part of multimodal treatment for oligometastatic prostate cancer
Trial: NCT05371223
Drug: Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic Nabpaclitaxel-Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each combined course is constituted by two consecutive 28-day cycles of systemic chemotherapy (three adminstrations per cycle: days 1,8 and 15) and one cycle of PIPAC administered within 10-13 days from the last administration of systemic chemotherapy. Between each combined course a 7-10 days pause is observed.~The recommended dose of Nabpaclitaxel in combination with Gemcitabine is 125 mg/m2 administered endovenous over 30 minutes on Days 1, 8 and 15 of each 28-day cycle. The concurrent recommended dose of Gemcitabine is 1000 mg/m2 administered intravenously over 30 minutes immediately after the completion of Nabpaclitaxel administration on Days 1, 8 and 15 of each 28-day cycle.~A pressurized aerosol containing Nabpaclitaxel at the dose of 112,5 mg/m2 diluted in a total volume of 200 ml of NaCl 0.9% is applied through the nebulizer inside the abdominal cavity during laparoscopy.
Trial: NCT04641975
Drug: Mirabegron
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral/ Oral Suspension: Participants with a body weight of ≥ 35 kg are to receive the tablet form of IP unless unable to swallow tablets and will be provided the oral suspension as an alternative. Participants with a body weight \< 35 kg or those who cannot be dosed with the tablet will receive oral suspension.
Trial: NCT04961515
Drug: Orelabrutinib
RxNorm normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orelabrutinib dose escalation will occur using a standard 3+3 dose-escalation approach to determined the maximum tolerated dose(MTD) of orelabrutinib dose in combined regimen, beginning at dose level I (150 mg daily) and potentially escalating to dose level 2 (200mg) and dose level 3 (250mg) with rules for escalation and de-escalation. If the DLT is not found, the dose of 250mg qd will be used for phase II trial.
Trial: NCT04961515
Drug: Orelabrutinib
RxNorm normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orelabrutinib: orally maximum tolerated dose from phase 1b daily (150 mg or 200 mg or 250mg)
Trial: NCT04961515
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of sintilimab is fixed dose. 200 mg intravenously every 3 weeks
Trial: NCT05304962
Drug: RGT-419B in combination with hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RGT-419B in combination with hormonal therapy (Selective Estrogen Receptor Degrader, Selective Estrogen Receptor Modulator, or Aromatase Inhibitor)
Trial: NCT05993234
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This is a non-interventional study and medication will be administered according to the SmPC as local standard of care and as part of the routine clinical practice.~T-DXd to be administered according to the SmPC. Conventional therapy (eg. platinum-fluoropyrimidine doublet chemotherapy, nivolumab, ramucirumab-paclitaxel, ramucirumab monotherapy, taxane or irinotecan, and pembrolizumab monotherapy) to be administered according to the SmPC.
Trial: NCT04344860
Drug: Tranexamic Acid Injection [Cyklokapron]
RxNorm normalized name: tranexamic acid Injection [Cyklokapron]
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (Cyclokapron) is an intravenous anti-fibrinolytic therapy that prevents clot breakdown and reduces bleeding with surgery or delivery.